Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

NHS England sees off AbbVie's Hep C legal challenge

NHS England sees off AbbVie's Hep C legal challenge

Maviret is in contention with rival treatments such as Gilead’s Sovaldi, Harvoni and Epclusa, to name a few. ... CAR-T therapy (Gilead/Kite’s Yescarta and Novartis’ Kymriah) and a deal to make the MSD’s groundbreaking Keytruda available for

Latest news

More from news
Approximately 140 fully matching, plus 298 partially matching documents found.

Latest Intelligence

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available.

  • Deal Watch October 2018

    Acquisition. $2B. Tango Therapeutics/. Gilead Sciences. Pipeline of up to 5 targeted immuno‐oncology. ... Acquisition. $463m. Precision BioSciences/. Gilead Sciences. ARCUS technology; targeting in vivo elimination of.

  • Redefining communications excellence Redefining communications excellence

    Gilead Sciences is among the companies to be lauded for running campaigns that could affect lives. ... Gilead also provided resources to help physicians talk to patients about sexual health.

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share. ... Gilead has also raised hopes after its candidate GS-9620, which aims to expel the virus from hidden reservoirs, made it through phase 1.

More from intelligence
Approximately 2 fully matching, plus 37 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics